Pedro de Marchi | Epidemiology | Academic Engagement Excellence Award

Posted on by ScienceFather

Dr. Pedro de Marchi | Epidemiology | Academic Engagement Excellence Award

Dr. Pedro de Marchi, ONCOCLINICAS, Brazil

Dr. Pedro de Marchi is a leading medical oncologist specializing in head and neck cancer at Oncoclínicas, Brazil. He serves as the National Leader and Medical Coordinator, alongside being a Professor of Medicine at Universidade Estadual do Rio de Janeiro. Dr. Marchi completed his MD at Universidade Federal de Santa Maria and furthered his training in internal medicine and oncology. His research focuses on the efficacy of immune checkpoint inhibitors and head and neck squamous cell carcinoma. Dr. Marchi has led several significant studies and has been involved in numerous conferences to advance cancer treatment. 🎗️👨‍⚕️📚

Publication Profile

Google Scholar

Education

Dr. Pedro de Marchi earned his MD from Universidade Federal de Santa Maria (UFSM) in 2008. He completed a residency in Internal Medicine at the Universidade Federal do Rio Grande do Sul and a Clinical Fellowship in Medical Oncology at Hospital São Lucas (PUC-RS). He further enriched his expertise through an observership at The University of Texas MD Anderson Cancer Center. Dr. Marchi holds a Master’s in Oncology from Fundação Pio XII, focusing on chemotherapy toxicity in head and neck cancer, and a PhD in Oncology, studying immune checkpoint inhibitors and biomarkers in lung cancer. 🎓💉📖

 

Experience and Service

Dr. Pedro de Marchi has an extensive career in oncology, serving as a resident at Universidade Federal do Rio Grande do Sul (2009-2011) and a Medical Oncology Fellow at Hospital São Lucas (2011-2014). He was the Head of Thoracic and Head & Neck Oncology at Barretos Cancer Hospital (2016-2020) and is currently a National Leader in Head & Neck Cancer at Oncoclínicas. In addition, he coordinates multiple fellowship programs and serves as a Professor of Medicine at Universidade Estadual do Rio de Janeiro. His leadership roles reflect his commitment to advancing oncology care and research. 🩺🌟📚

 

Honors and Awards

Dr. Pedro de Marchi was recognized with the AMRIGS Medical Qualification by the Medical Association of Rio Grande do Sul in Porto Alegre, Brazil, in 2008. This prestigious honor highlights his dedication to the medical field and his commitment to achieving excellence in healthcare. The award underscores his professional qualifications and serves as a testament to his skills as a medical practitioner. Dr. de Marchi’s achievements reflect his continuous pursuit of knowledge and his contribution to advancing medical practice in Brazil. 🏆🎓🌟

 

Research Contributions

Dr. Pedro de Marchi has made significant contributions to cancer research through various grants and contracts. As the Principal Investigator, he led studies on head and neck squamous cell carcinoma epidemiology and COVID-19 mortality determinants among cancer patients, securing substantial funding from notable organizations like MSD, AMGEN, and AstraZeneca. His research includes pivotal Phase III trials assessing innovative treatments for squamous cell carcinoma. These efforts not only advance medical knowledge but also aim to improve patient outcomes in Brazil. Dr. de Marchi’s work is essential in addressing critical health challenges in oncology. 📊🔬🎗️

 

Teaching

Dr. Pedro de Marchi plays a vital role in medical education and mentorship. He serves as a Clinical Research Mentor in the Oncoclinicas Mentorship Programme since 2024, fostering the next generation of oncologists. As a Professor at Universidade Estadual do Rio de Janeiro (UERJ), he instructs rotating medical students, enhancing their clinical skills. Additionally, Dr. de Marchi supervises postdoctoral research fellows in Internal Medicine and Thoracic and Head & Neck Medical Oncology, guiding them in their academic and clinical pursuits. His commitment to education ensures that future physicians are well-equipped for the challenges of oncology. 📚👨‍⚕️🎓

 

Conclusion

Dr. Pedro de Marchi exemplifies the qualities sought after for the Research for Academic Engagement Excellence Award. His leadership in cancer research, dedication to education, and significant contributions to the field make him a suitable candidate for this prestigious recognition.

Publication Top Notes

  • Pembrolizumab versus chemotherapy for untreated PD-L1-expressing NSCLC (KEYNOTE-042) 🌟 — Cited by: 3065, Year: 2019
  • Durvalumab plus platinum–etoposide for extensive-stage SCLC (CASPIAN) 🎯 — Cited by: 1679, Year: 2019
  • First-line nivolumab plus ipilimumab and chemotherapy in NSCLC (CheckMate 9LA) 🚀 — Cited by: 1086, Year: 2021
  • Durvalumab with/without tremelimumab for extensive-stage SCLC (CASPIAN) ⚖️ — Cited by: 487, Year: 2021
  • CheckMate 9LA 2-year update: nivolumab plus ipilimumab and chemotherapy vs. chemotherapy alone 🕒 — Cited by: 172, Year: 2021
  • Lung cancer in Brazil 🇧🇷 — Cited by: 142, Year: 2018
  • PD-L1 expression in NSCLC: TPS vs. CPS 🧬 — Cited by: 77, Year: 2021
  • Câncer de pulmão no Brasil 📈 — Cited by: 70, Year: 2018
  • MiR-21 as a prognostic biomarker in head and neck SCC 📊 — Cited by: 69, Year: 2017
  • Determinants of COVID-19 mortality in cancer patients in Brazil 🦠 — Cited by: 50, Year: 2021

Abdilahi Ibrahim Muse | Public health | Best Researcher Award

Posted on by ScienceFather

Mr. Abdilahi Ibrahim Muse | Public health | Best Researcher Award

Mr. Abdilahi Ibrahim Muse, Jigjiga University, Ethiopia

Abdilahi Ibrahim Muse is an experienced educator and clinical coordinator at Jigjiga University, Ethiopia, specializing in Nursing and Midwifery. With a Senior B.Sc. in Nursing and an MPH in Nutrition, he excels in clinical education, student mentorship, and curriculum development. Abdilahi’s research focuses on public health issues like under-nutrition among TB and HIV patients in the Somali region. He is skilled in statistical software and has collaborated with various institutions, including the Ethiopian Public Health Institute and Addis Ababa University, on qualitative data collection. Abdilahi is known for his strong communication skills and commitment to healthcare improvement. 🏥

Publication profile

Scopus

Orcid

 

🎓 Teaching and Academic

Abdilahi prepares and delivers lectures, engages students in active learning, and contributes to curriculum development. He is dedicated to enhancing student outcomes through practical sessions and updated instructional materials.

Research Focus

Abdilahi Ibrahim Muse’s research primarily focuses on public health challenges in the Somali region, East Ethiopia, with a particular emphasis on undernutrition among adult tuberculosis patients, non-adherence to antiretroviral therapy in HIV patients, and mortality risk factors among adult stroke patients. His contributions, published in reputable journals like Research and Reports in Tropical Medicine and International Journal of Africa Nursing Sciences, underscore his commitment to improving healthcare outcomes through rigorous epidemiological studies and cohort designs. Abdilahi’s work integrates statistical analysis tools like SPSS and STATA, reflecting his proficiency in data-driven research methodologies aimed at addressing critical health issues. 🩺

 

Publication Top Notes

  • “Incidence of mortality and risk factors among adult stroke patients in public hospitals Jigjiga town Somali region, Ethiopia: Cohort study design,” SAGE Open Medicine, 2024.
  • “Non-adherence to antiretroviral therapy and associated factors among adult HIV patients in Somali region public Hospitals, eastern Ethiopia,” International Journal of Africa Nursing Sciences, 2023.
  • “Undernutrition and Associated Factors Among Adult Tuberculosis Patients in Jigjiga Public Health Facilities, Somali Region, East, Ethiopia,” Research and Reports in Tropical Medicine, 2021.